Search

Displaying results 4811 - 4820 of 9333 in total
  1. Drug

    TG-100801

    go.drugbank.com/drugs/DB05075
    Investigational

    It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological … hallmarks of AMD and other back of the eye diseases including diabetic macular edema and proliferative diabetic retinopathy.

  2. Drug

    Vapitadine

    go.drugbank.com/drugs/DB05738
    Experimental

    An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses. … Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis

  3. Drug

    Eptazocine

    go.drugbank.com/drugs/DB19670
    Experimental

    The usage of the INN stem '-azocine' in the name indicates that Eptazocine is a narcotic antagonist/agonist related to 6,7-benzomorphan. Eptazocine has a monoisotopic molecular weight of 231.16 Da.

  4. Drug

    Decoquinate

    go.drugbank.com/drugs/DB11394
    ExperimentalVet approved

    Decoquinate is used in veterinary to delay the growth and reproduction of coccidian parasites.

  5. Drug

    Recombinant Cholera Toxin B Subunit

    go.drugbank.com/drugs/DB11643
    ApprovedInvestigational

    Recombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.

  6. Drug

    Ferrimannitol ovalbumin

    go.drugbank.com/drugs/DB15824
    Investigational

    Ferrimannitol-ovalbumin (FMOA) is an adduct between ovalbumin and the complex Fe(III)-mannitol.

  7. Drug

    Yttrium Y-90

    go.drugbank.com/drugs/DB13076
    ApprovedInvestigational

    Yttrium 90 has been investigated for the treatment of Colon Cancer and Colorectal Cancer.

  8. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease … Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard

  9. Drug

    Inhibitor of P38 Kinase

    go.drugbank.com/drugs/DB01953
    Experimental

    This compound belongs to the indoles. These are compounds containing an indole moiety, which consists of a pyrrole ring fused to benzene to form 2,3-benzopyrrole. … This drug is known to target mitogen-activated protein kinase 14.

  10. Drug

    Bevirimat

    go.drugbank.com/drugs/DB06581
    Investigational

    This compound belongs to the androgens and derivatives, which are hydroxylated C19 steroid hormones. They are known to favour the development of masculine characteristics. … It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos.